Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same

Abstract

Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial.

1 . A method for treating a skin ulcer in a mammal, the method comprising adding to a solution comprising an effective amount of hypochlorous acid, wherein the hypochlorous acid solution comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof, wherein the hypochlorous acid has a pH of about 4 to about 6, and a second component comprising triethanolamine, wherein when the first and second components are combined, the combination produces an activated solution comprising a therapeutically effective amount of dichlorine monoxide, and wherein the activated solution has a pH in a range of from about 4 to about 10, and administering the activated solution to the mammal to treat the skin ulcer. 
     
     
         2 . The method of  claim 1 , wherein the triethanolamine is present in a concentration of about 0.3 ppm to about 1.5 ppm. 
     
     
         3 . The method of  claim 1 , wherein the buffer is a phosphate buffer. 
     
     
         4 . The method of  claim 1 , wherein the activated solution has a pH of from about 5.0 to about 6.0. 
     
     
         5 . The method of  claim 1 , wherein the skin ulcer is selected from the group consisting of a diabetic foot ulcer, an ischemic ulcer, a gangrenous ulcer, a venous stasis ulcer, a decubitus ulcer, or a traumatic ulcer. 
     
     
         6 . The method of  claim 1  wherein the skin ulcer is a diabetic foot ulcer. 
     
     
         7 . The method of  claim 1 , wherein the skin ulcer is in a patient with arterial insufficiency, wherein the arterial insufficiency is caused by atherosclerosis, hypertension, smoking, emboli, arterial inflammation, graft-versus-host disease, Raynaud's Disease, Buerger Disease, or combinations thereof. 
     
     
         8 . The method of  claim 1 , wherein the skin ulcer is treated by administering the activated solution to the skin ulcer. 
     
     
         9 . A method for treating a sinus infection in a mammal, the method comprising adding to a solution comprising an effective amount of hypochlorous acid, wherein the hypochlorous acid solution comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof, wherein the hypochlorous acid has a pH of about 4 to about 6,and a second component comprising triethanolamine, wherein when the first and second components are combined, the combination produces an activated solution comprising a therapeutically effective amount of dichlorine monoxide, and wherein the activated solution has a pH in a range of from about 4 to about 10, and administering the activated solution to the mammal to treat the sinus infection. 
     
     
         10 . The method of  claim 9 , wherein the triethanolamine is present in a concentration of about 0.3 ppm to about 1.5 ppm. 
     
     
         11 . The method of  claim 9 , wherein the buffer is a phosphate buffer. 
     
     
         12 . The method of  claim 9 , wherein the activated solution has a pH of from about 5.0 to about 6.0. 
     
     
         13 . The method of  claim 9 , wherein the activated solution is administered to a nasal passage in an atomized form. 
     
     
         14 . A method for treating a patient that has or is at risk of developing peritonitis, the method comprising adding to a solution comprising an effective amount of hypochlorous acid, wherein the hypochlorous acid solution comprises a buffer selected from the group consisting of a phosphate buffer, acetate buffer, citrate buffer, borate buffer, and combinations thereof, wherein the hypochlorous acid has a pH of about 4 to about 6, and a second component comprising triethanolamine, wherein when the first and second components are combined, the combination produces an activated solution comprising a therapeutically effective amount of dichlorine monoxide, and wherein the activated solution has a pH in a range of from about 4 to about 10, and administering the activated solution to the mammal to treat the peritonitis. 
     
     
         15 . The method of  claim 14 , wherein the triethanolamine is present in a concentration of about 0.3 ppm to about 1.5 ppm. 
     
     
         16 . The method of  claim 14 , wherein the buffer is a phosphate buffer. 
     
     
         17 . The method of  claim 14 , wherein the activated solution has a pH of from about 5.0 to about 6.0. 
     
     
         18 . The method of  claim 14 , wherein the activated solution is administered to a peritoneal space of the patient by lavage. 
     
     
         19 . The method of  claim 14 , wherein the risk of developing adhesions or abscesses associated with peritonitis in the patient is reduced.